

## NET ASSET VALUE – 31 October 2024

On the 31 October 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,377 million and NAV per share was SEK 56.06.

Allocation of NAV	Share of portfolio company	Fair value (MSEK)	Part of NAV per share (SEK)	Share of NAV
<b>Product Development</b>				
Prokarium	42%	488	6.25	11.1%
Xspray Pharma	18%	351	4.50	8.0%
Empros Pharma	79%	204	2.62	4.7%
KAHR Medical	31%	202	2.59	4.6%
Atrogi	37%	176	2.25	4.0%
Lipum	57%	173	2.22	4.0%
Xintela	56%	143	1.84	3.3%
Microbiotica	11%	139	1.78	3.2%
Mendus	24%	123	1.57	2.8%
Geneos Therapeutics	12%	103	1.31	2.3%
Toleranzia	66%	90	1.15	2.1%
EpiEndo Pharmaceuticals	9%	58	0.74	1.3%
Synerkine Pharma	43%	53	0.68	1.2%
AnaCardio	19%	52	0.66	1.2%
Egetis Therapeutics	2%	31	0.40	0.7%
Buzzard Pharmaceuticals	14%	29	0.37	0.7%
Vitara Biomedical	8%	29	0.37	0.7%
Sixera Pharma	23%	26	0.33	0.6%
Alder Therapeutics	21%	17	0.22	0.4%
Amarna Therapeutics	58%	12	0.15	0.3%
Strike Pharma	16%	9	0.11	0.2%
<b>Total</b>		<b>2,507</b>	<b>32.11</b>	<b>57.3%</b>
<b>Commercial Growth</b>				
NorthX Biologics	92%	189	2.42	4.3%
Symcel	31%	169	2.16	3.9%
Provell Pharmaceuticals	72%	75	0.96	1.7%
Chromafora	31%	73	0.93	1.7%
Nanologica	38%	71	0.91	1.6%
A3P Biomedical	8%	42	0.54	1.0%
Frontier Biosolutions	2%	19	0.25	0.4%
Bohus Biotech	45%	17	0.21	0.4%
<b>Total</b>		<b>654</b>	<b>8.38</b>	<b>14.9%</b>
<b>Limited Partnerships, total</b>				
		<b>94</b>	<b>1.21</b>	<b>2.2%</b>
Assets related to Portfolio companies		316	4.05	7.2%

Other assets and liabilities		805	10,31	18.4%
<b>Net asset value</b>		<b>4,377</b>	<b>56.06</b>	<b>100.0%</b>

\* indirect shares in Provell Pharmaceuticals

**For more information:**

Ted Fjällman, CEO  
Email: [ir@flerie.com](mailto:ir@flerie.com)

**Flerie in brief**

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit [www.flerie.com](http://www.flerie.com)

**Attachments**

[NET ASSET VALUE – 31 October 2024](#)